<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7948">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872534</url>
  </required_header>
  <id_info>
    <org_study_id>PL-ASA-002</org_study_id>
    <nct_id>NCT00872534</nct_id>
  </id_info>
  <brief_title>Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single-Blind, Endoscopic Evaluation Of Upper GI Mucosal Damage Induced By PL-2200 Versus Aspirin In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PLx Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PLx Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by
      assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective
      doses of aspirin (325 mg) in normal healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of Subjects With Gastroduodenal Erosions and Ulcers.</measure>
    <time_frame>After 7 days of study medication</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of subjects with gastroduodenal composite scores of 3 or 4 (&gt; 5 erosions or 1 or more ulcers 3 mm or greater in length with unequivocal depth).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Upper Gastrointestinal Mucosal Damage</condition>
  <arm_group>
    <arm_group_label>PL-2200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate release 325mg aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>325mg once a day for 7 days</description>
    <arm_group_label>PL-2200</arm_group_label>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥50 to ≤75 years of age.

          -  Subject is healthy.

          -  Subject has a BMI between 20 and 32

          -  If female and of child bearing potential, subject has a negative pregnancy test and
             is not nursing.

        Exclusion Criteria:

          -  Subject has abnormal screening/baseline laboratory parameters or endoscopic
             observations deemed clinically significant by the Investigator.

          -  Subject has an active Helicobacter pylori infection.

          -  Subject has a prior GI ulcer, bleeding, obstruction or perforation.

          -  Subject has taken aspirin or any aspirin containing product within the last 4 weeks,
             or a non-aspirin NSAID product within 2 weeks.

          -  Subject has taken any of the following medications within 2 weeks prior to
             enrollment: Any anti-platelet agents, anti-coagulants or selective serotonin reuptake
             inhibitors.

          -  Subject has used an investigational agent within the past 30 days.

          -  Subject has hypersensitivity or contraindications to aspirin, ibuprofen, or other
             NSAID.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byron L Cryer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dallas VA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank L Lanza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Houston Institute for Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael E Schwartz, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jupiter Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan J Kivitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altoona Arthritis and Osteoporosis Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phillip B Miner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma Foundation for Digestive Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jupiter Research</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Foundation for Digestive Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Arthritis and Osteoporosis Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Center For Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 5, 2015</lastchanged_date>
  <firstreceived_date>March 10, 2009</firstreceived_date>
  <firstreceived_results_date>June 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>To evaluate the acute gastrointestinal safety of PL-2100.</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PL-2200</title>
          <description>PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
acetylsalicylic acid: 325mg once a day for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Aspirin</title>
          <description>Immediate release 325mg aspirin
acetylsalicylic acid: 325mg once a day for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PL-2200</title>
          <description>PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
acetylsalicylic acid: 325mg once a day for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Aspirin</title>
          <description>Immediate release 325mg aspirin
acetylsalicylic acid: 325mg once a day for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="100"/>
                <measurement group_id="B2" value="104"/>
                <measurement group_id="B3" value="204"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58.1" spread="6.35"/>
                <measurement group_id="B2" value="56.6" spread="6.00"/>
                <measurement group_id="B3" value="57.3" spread="6.20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="88"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="56"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="116"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Subjects With Gastroduodenal Erosions and Ulcers.</title>
        <description>Incidence of subjects with gastroduodenal composite scores of 3 or 4 (&gt; 5 erosions or 1 or more ulcers 3 mm or greater in length with unequivocal depth).</description>
        <time_frame>After 7 days of study medication</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>PL-2200</title>
            <description>PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
acetylsalicylic acid: 325mg once a day for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Immediate release 325mg aspirin
acetylsalicylic acid: 325mg once a day for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                  <measurement group_id="O2" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Subjects With Gastroduodenal Erosions and Ulcers.</title>
            <description>Incidence of subjects with gastroduodenal composite scores of 3 or 4 (&gt; 5 erosions or 1 or more ulcers 3 mm or greater in length with unequivocal depth).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Gastroduodenal Composite Score of 3 or 4 (NO)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                  <measurement group_id="O2" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastroduodenal Composite Score of 3 or 4 (YES)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PL-2200</title>
          <description>PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
acetylsalicylic acid: 325mg once a day for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Aspirin</title>
          <description>Immediate release 325mg aspirin
acetylsalicylic acid: 325mg once a day for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Stomach Ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Standard Confidentiality Agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Zimmerman, CEO &amp; President</name_or_title>
      <organization>PLx Pharma</organization>
      <phone>1-713-842-1249 ext 205</phone>
      <email>ron.zimmerman@plxpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
